N-(5-chlorobenzooxazol-2-yl)3-(4-nitrophenyl)acrylamide | 924624-27-1

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: N-(5-chlorobenzooxazol-2-yl)3-(4-nitrophenyl)acrylamide
• 英文别名: (E)-N-(5-chloro-1,3-benzoxazol-2-yl)-3-(4-nitrophenyl)prop-2-enamide
• CAS: 924624-27-1
• 化学式: C₁₆H₁₀ClN₃O₄
• 分子量: 343.726
• InChiKey: CWQLTSJJIKPWQU-FPYGCLRLSA-N

物化性质

• 密度：
  1.525±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  101
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  苯并恶唑胺 、 反-4-硝基肉桂酰氯 在 三乙胺 作用下， 以 苯 为溶剂， 反应 1.5h， 以37%的产率得到N-(5-chlorobenzooxazol-2-yl)3-(4-nitrophenyl)acrylamide
  参考文献：
  名称：

  SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE

  摘要：

  这项发明涉及化合物、其药物组合物以及抑制鞘氨醇激酶并治疗或预防过度增殖性疾病、炎症性疾病或血管生成性疾病的方法。

  公开号：

  US20070032531A1

文献信息

• Sphingosine Kinase Inhibitors and Methods of Their Use
  申请人：Smith Charles D.

  公开号：US20100137315A1

  公开（公告）日：2010-06-03

  The invention relates to compounds, pharmaceutical compositions thereof, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.

  该发明涉及化合物，其制药组合物以及抑制鞘氨醇激酶和治疗或预防过度增生性疾病，炎症性疾病或血管生成性疾病的方法。
• Treatment Of Ischemia-Reperfusion Injury
  申请人：Smith Charles D.

  公开号：US20120122870A1

  公开（公告）日：2012-05-17

  Ischemia-reperfusion injury remains a primary cause of morbidity and mortality in individuals who experience disruption of normal blood flow to one or more major organs. For example, there are no clinically proven strategies that prevent acute renal failure following cardiac surgery. The present invention provides a variety of methods for the treatment or prevention of ischemia-reperfusion injury. In one aspect of the invention, a method for treating or preventing ischemia-reperfusion injury includes administering to a subject an effective amount of a sphingosine kinase inhibitor. Sphingosine kinase inhibitors are very effective in the protection against IR-induced acute renal failure and liver failure. Moreover, the effects occur very early after administration, requiring only a very short time of treatment. Toxicology studies with sphingosine kinase inhibitors demonstrate that they have low toxicity, even in long-term treatment.
• [EN] SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE<br/>[FR] INHIBITEURS DE LA SPHINGOSINE KINASE ET LEURS METHODES D'UTILISATION
  申请人：APOGEE BIOTECHNOLOGY CORP

  公开号：WO2007019251A2

  公开（公告）日：2007-02-15

  (EN) The invention relates to compounds, pharmaceutical compositions thereof, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.(FR) L'invention concerne des composés, des compositions pharmaceutiques contenant ces composés, ainsi que des méthodes destinées à l'inhibition de la sphingosine kinase et au traitement ou à la prévention de maladies hyperprolifératives, inflammatoires ou angiogéniques.
• SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE
  申请人：Smith D. Charles

  公开号：US20070032531A1

  公开（公告）日：2007-02-08

  The invention relates to compounds, pharmaceutical compositions thereof, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease,

  这项发明涉及化合物、其药物组合物以及抑制鞘氨醇激酶并治疗或预防过度增殖性疾病、炎症性疾病或血管生成性疾病的方法。